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Abstract
Hepadnaviruses including human hepatitis B virus (HBV) and duck hepatitis B virus (DHBV) express X proteins, HBx and DHBx,
respectively. Both HBx and DHBx are transcriptional activators and modulate cellular signaling in in vitro assays. To test whether the DHBx
protein plays a role in virus infection, we compared the in vivo infectivity and growth characteristics of a DHBV3 strain with a stop codon
in the X-like ORF (DHBV3-X-K.O.) to those of the wild-type DHBV3 strain. Here we report that the two strains showed no significant
difference in (i) their ability to induce infection that resulted in stable viraemia measured by serum surface antigen (DHBsAg) and DHBV
DNA, and detection of viral proteins and replicative DNA intermediates in the liver; (ii) the rate of spread of infection in liver and
extrahepatic sites after low-dose virus inoculation; and (iii) the ability to produce transient or persistent infection under balanced age/dose
conditions designed to detect small differences between the strains. Thus, none of the infection parameters assayed were detectably affected
by the X-ORF knockout mutation, raising the question whether DHBx expression plays a physiological role during in vivo infection with
wild-type DHBV.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Hepadnaviruses are small, enveloped DNA viruses con-
taining a partially double-stranded, relaxed circular DNA
(rcDNA) genome with a size of 3.0–3.3 kb. Following
infection of a host cell, the rcDNA is converted into co-
valently closed circular DNA (cccDNA) in the nucleus
(Tuttleman et al., 1986). This cccDNA is transcribed by the
host RNA polymerase II to produce subgenomic mRNAs
and a greater-than-genome-length RNA called pregenomic
RNA (pgRNA). All hepadnaviruses replicate by reverse
transcription of pgRNA into rcDNA. Messenger RNA spe-
cies encode the envelope proteins, the nucleocapsid or core
protein, the polymerase protein, and in mammalian hepad-
naviruses, the X protein. HBV and woodchuck hepatitis
virus (WHV) both express X proteins, HBx and WHx,
respectively, in vivo (Feitelson et al., 1993; Kay et al.,
1985), and HBx- and WHx-specific immune responses can
be detected in infected individuals (Jacob et al., 1997; Mo-
riarty et al., 1985). A variety of functions have been de-
scribed for these X proteins using in vitro assays, including
transactivation of viral and cellular promoters as well as
proapoptotic properties and a possible role in the develop-
ment of HCC (see Diao et al., 2001, for a review).
Avihepadnaviruses isolated from gray herons, snow
geese, a Ross goose, and white storks also have an open
reading frame (ORF) in a position similar to that of the X
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gene of mammalian hepadnaviruses (Chang et al., 2001).
However, putative X proteins derived from these ORFs are
smaller in size, ranging from 66 to 87 amino acids (aa),
compared to HBx (154 aa) and WHx (141 aa). It was
recently proposed that the smaller size of the avian X
proteins has resulted from insertion of stop codons upstream
of the X-like ORFs during evolution, thus preventing ex-
pression of larger and structured X proteins similar to those
in the mammalian hepadnaviruses (Lin and Anderson,
2000). More than 20 DHBV isolates have been described
and cluster into the “Chinese” and “Western country” iso-
lates (Triyatni et al., 2001). DHBV strains also contain an
X-like ORF similar in length to those of other avihepadna-
viruses, but the X-like ORF does not have an AUG start
codon. However, an X-like protein has been detected in
DHBV-infected liver using antipeptide antibodies; it has
been proposed that this may be expressed with a length of
up to 114 aa using a nonconventional start codon (Chang et
al., 2001).
Little is known about the possible in vivo functions of X
proteins. In initial experiments woodchucks transfected
with WHV genomes containing a truncated WHx or a
WHx-K.O. showed no signs of infection (Chen et al., 1993;
Zoulim et al., 1994). However, in more recent in vivo
experiments, animals transfected with WHV genomes con-
taining mutations in the WHx ORF demonstrated evidence
of low-level WHV infection, with transient viraemia and the
development of anti-WHV core and/or anti-WHV surface
antibodies (Zhang et al., 2001). In these studies the WHx
mutants reverted to wt within 2 weeks of infection, suggest-
ing a selective advantage for wt strains expressing WHx
protein and an important role for the X protein in vivo. In
transgenic mice carrying an integrated HBV DNA with
mutations in the HBx ORF, virus replication and virion
export still occurred with comparable HBcAg levels in the
liver to those observed in transgenic mice with wt HBV
(Reifenberg et al., 2002).
Thus, circumstantial evidence suggests that the X protein
may play some important as yet undefined role in the overall
process of in vivo infection; however, this has not been
correlated with the spectrum of effects described for X
protein in vitro. In vivo systems are available for DHBV and
can be used to explore the function of X. We therefore
wished to test, as a starting point, whether the DHBx protein
plays a role in virus infection in vivo by comparing the
infectivity and growth characteristics of the wt DHBV3
strain, with the DHBV3-X-K.O. strain containing a stop
codon in the putative DHBx-ORF (Chang et al., 2001).
Specifically, we aimed to produce infectious stocks of each
strain and to compare the strains in terms of their infectious
dose, the rate and level of virus spread in vivo, and the
ability to cause acute or persistent infections under age/
dose-controlled conditions. These results were compared
with data from experiments with the Australian strain of
DHBV (AusDHBV) (Jilbert et al., 1996, 1998; Triyatni et
al., 2001). None of the infection parameters assayed were
detectably affected by the X-ORF knockout mutation, rais-
ing the question of whether DHBx expression plays a phys-
iological role during in vivo infection with wt DHBV.
Results
Generation and analysis of infectious virus stocks
One- to 2-day-old DHBV-negative ducks were inocu-
lated intrahepatically (ih) and/or intravenously (iv) with 100
g of plasmid containing a head-to-tail dimer of the genome
of DHBV3 or DHBV3-X-K.O. (Chang et al., 2001) and
monitored for serum DHBsAg using a standard screening
ELISA (Jilbert et al., 1996). Of five ducks inoculated with
pDHBV3, two (1305, 1309) remained DHBsAg-negative;
one (1304) showed a low and transient viremia at day 14
postinoculation (p.i.) only, and two (1310, 1311) developed
significant viraemia by day 8 (Fig. 1A). Of three ducks
inoculated with pDHBV3-X-K.O., two (1306, 1308)
showed viremia at day 10 p.i. and one (1307) remained
DHBV-negative throughout the observation period (Fig.
1B).
Fig. 1. Development of antigenemia following DHBV DNA transfection.
One- to 2-day-old DHBV-negative ducks were inoculated ih and/or iv with
100 g of plasmid containing a head-to-tail dimer of the genome of
DHBV3 (A) or DHBV3-X-K.O. (B) and monitored for serum DHBsAg by
ELISA. Serum samples from animals 1311 (DHBV3) and 1306 (DHBV3-
X-K.O.) were collected at the time of autopsy and used as infectious viral
stocks for future experiments. OD, optical density (490 nm).
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Serum samples from animals 1311 (DHBV3) and 1306
(DHBV3-X-K.O.) were collected at the time of autopsy
(days 8 and 10 p.i., respectively) and used as infectious
stocks for future experiments. Each of the stocks was tested
by quantitative DHBsAg ELISA and found to contain 110
and 140 g/ml of DHBsAg for DHBV3 and DHBV3-X-
K.O., respectively (Table 1). Viral genome equivalents/ml
(vge/ml) determined by quantitative PCR were 3.1  1010
and 1.0  1010 for DHBV3 and DHBV3-X-K.O., respec-
tively. For the determination of the ID50 of the viral stocks,
1- to 2-day old ducks were inoculated iv with dilutions of
each stock containing the equivalent of 10,000, 1000, 100,
10, 1, and 0.1 vge and then bled twice a week for 4 weeks.
Infection was detected by the appearance of DHBsAg in
serum and the presence of DHBsAg in autopsy liver sec-
tions (days 11–33 p.i.), which gave concordant results. Se-
rum stocks from each strain were found to have similar ID50
titers (Reed and Muench, 1938) and had ratios of DNA
genomes/infectious particle of 18 and 4 for the DHBV3 and
DHBV3-X-K.O. strains, respectively, similar to those ob-
served using pooled serum from ducks congenitally infected
with an AusDHBV (Table 1) (Jilbert et al., 1996).
Spread of virus infection following low-dose viral
inoculation
One- to 2-day-old DHBV-negative ducks were inocu-
lated iv with 100 l of diluted duck serum containing 1500
ID50 of DHBV3 (1311) and DHBV3-X-K.O. (1306). Each
day from days 3 to 14 p.i., two animals from each group
were autopsied for detailed examination. No marked pathol-
ogy was observed in liver sections, including assessment of
bile-duct cell proliferation, and fat and glycogen content,
and no differences were seen between DHBV3, DHBV3-
X-K.O., and uninfected ducks (not shown). DHBsAg-posi-
tive hepatocytes were first detected at day 4 p.i. for DHBV3
with 0.04 and 0.08% infected cells (Figs. 2A and B), while
with DHBV3-X-K.O. DHBsAg was first seen at day 5 p.i.
(0.005 and 0.07% of hepatocytes DHBsAg-positive). From
days 4 (DHBV3) or 5 p.i. (DHBV3-X-K.O.) an exponential
increase in infected cells was observed up to days 7 to 8 p.i.,
after which time 95% of hepatocytes remained DHBsAg-
positive.
Viral replicative intermediates (RI) including double-
stranded linear (dsl), single-stranded (ss), and relaxed cir-
cular (rc) DNA were first detected in the liver by Southern
blot hybridisation at day 6 p.i. for both strains and peaked at
days 8–9 (Fig. 2C). The amount of RI detected corre-
sponded to the percentage of hepatocytes infected, i.e., a
slight delay was seen for DHBV3-X-K.O. until day 8 p.i.
Western blot analysis from fully infected livers showed two
bands at 28 and 36 kDa for DHBsAg (Fernholz et al., 1993)
and one band at 32 kDa for DHBcAg (Sprengel et al., 1988).
Expression levels of both DHBsAg and DHBcAg were
similar for DHBV3 and DHBV3-X-K.O. (Fig. 2D).
DHBsAg was first detected in serum at low levels at day
6 p.i. for two ducks inoculated with DHBV3 and for one
duck inoculated with DHBV3-X-K.O. Serum DHBsAg lev-
els in all ducks peaked at around day 9 p.i. and then declined
by 0.5–1 log (Fig. 3A). The two strains showed no signif-
icant differences in serum DHBsAg content. DHBV DNA
was first detected in serum using quantitative PCR at day
3 p.i. for both strains and the levels peaked at day 9 p.i.
before declining by 0.5–1 log, consistent with DHBsAg
serum levels (Fig. 3B). Again, DHBV3 and DHBV3-X-
K.O. showed no significant differences in serum DHBV
DNA content.
DHBsAg in extrahepatic tissue was first detected in renal
glomeruli at day 7 p.i. and thereafter for both virus strains
(data not shown). Detection of DHBsAg in glomeruli has
been associated with immune complexes, indicating an
early antiviral humoral immune response (Freiman et al.,
1988). Staining of DHBsAg in spleen, especially in either
peri-ellipsoid cells within the periarteriolar lymphoid sheath
and/or in germinal centers, was observed as soon as the liver
was fully infected, although not in all animals. Occasional
staining of single acinar cells was observed in pancreas
from day 10 p.i. onward, which has been shown to involve
DHBV replication (Jilbert et al., 1988). No differences re-
garding infection of extrahepatic tissue were observed be-
tween DHBV3- and DHBV3-X-K.O.-inoculated animals.
Age/dose-related outcomes of infection
We have shown before that whether an acute or persis-
tent infection will occur depends on the age of ducks and the
dose of the DHBV used in the inoculum (Jilbert et al.,
1998). To examine whether expression of DHBx might
influence these outcomes, 14-day-old ducks were inoculated
with defined doses of the DHBV3 or DHBV3-X-K.O.
strains. Serum samples of the inoculated ducks were ana-
lyzed for DHBsAg twice a week for 5 to 9 weeks p.i. by
ELISA. Ducks that developed persistent infection showed
similar liver histology and distribution of DHBsAg in liver
and extrahepatic sites to the persistently infected ducks
described in the previous section. All animals inoculated
Table 1
Comparison of DHBV wt and DHBV3-X-K.O. serum stocks
DHBV3 wta DHBV3-X-K.O.b AusDHBVc
DHBsAg [g/ml] 110 140 50
DNA content [vge/ml] 3.1  1010 1.0  1010 2.3  1010d
ID50/ml 2.5  109e 3.4  109e 2.8  109e
Ratio IP/vgef 1/18 1/4 1/12
a, b The serum stocks used were derived from duck 1311 and 1306,
respectively.
c, d A virus stock was used that was different to the one used in previ-
ously published data (Jilbert et al., 1996), and quantitative PCR was used
for DHBV DNA determination instead of southern blot hybridisation.
e The 95% confidence limits were 1.03 log10 units.
f IP, infectious particles  0.67  ID50.
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Fig. 2. Spread of virus in the liver. One- to 2-day-old DHBV-negative ducks were inoculated iv with 1500 ID50 of DHBV3 and DHBV3-X-K.O. Each day
from days 3 to 14 p.i., two ducks from each group were autopsied and analyzed. (A) Liver sections collected on days 5–7 p.i. during the exponential phase
of spread were stained for DHBsAg using 1H.1 monoclonal antibodies. Cell counts were performed as described under Materials and methods and resulting
percentages of DHBsAg-positive hepatocytes were as indicated. The one duck of the pair analyzed exhibiting the higher percentage of infected cells is shown
for each strain and each day. (B) Detection in DHBsAg-positive hepatocytes from days 4–14 p.i. Each symbol represents the percentage of infected
hepatocytes in an individual duck. The lines shown are regression curves of data from the exponential phase of spread of DHBV3 and DHBV3-X-K.O., i.e.,
from days 4–7 p.i. (C) Southern blot hybridization of replicative intermediates. Seven micrograms of total DNA isolated from liver tissue from two ducks
per strain per day was loaded into each lane. Percentages of infected hepatocytes for each duck are indicated for comparison. M, marker, 40 pg of linear
DHBV DNA; rc, relaxed circular, dsl, double-stranded linear, and ss, single-stranded forms of viral DHBV DNA. (D) Western blot analysis. One hundred
micrograms of total protein was loaded into each lane of a 12% polyacrylamide gel and after blotting DHBsAg and DHBcAg were detected using the 1H.1
monoclonal antibodies (specific to the PreS region of PreS/S) and rabbit serum containing antirecombinant DHBcAg antibodies, respectively. Wt, DHBV3
wild-type; X-KO, DHBV3-X-K.O.
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with the highest dose, i.e., 108 ID50, showed persistent
infection, as expected from earlier results with the Aus-
DHBV strain (Table 2) (Jilbert et al., 1998). Lower doses of
104 and 106 ID50 induced persistence only in 6/16 of the
DHBV3-infected ducks and 4/16 of the DHBV3-X-K.O.-
infected ducks, again showing no significant difference be-
tween the two strains.
Aspartate aminotransferase (AST), alanine aminotrans-
ferase (ALT), and gamma-glutamyl transferase (GGT) lev-
els in serum from DHBV3- and DHBV3-X-K.O.-inoculated
ducks analyzed on days 18 and 39 p.i. were mostly within
normal ranges (Foster et al., 2003) and revealed no differ-
ences between the two strains (data not shown). Finally, in
those ducks that developed persistent infection with the
DHBV3 or DHBV3-X-K.O. strains with DHBsAg expres-
sion in 95% hepatocytes, the levels of expression of DH-
BsAg and DHBcAg in the liver were similar when mea-
sured by Western blot (data not shown).
Possible selection of X-expression revertant virus
It was possible that impaired fitness of the DHBV3-X-
K.O. strain in vivo may not have been detected if rapid
reversion to wt virus occurred soon after in vivo infection.
However, serum samples from a total of 13 ducks inocu-
lated with DHBV3-X-K.O. collected on days 10, 11, 13, 14,
35, 46, and 63 p.i. and the serum stock 1306 showed no
reversion to wt when monitored by sequencing the X ORF
of DHBV DNA amplified by PCR and using the amplifica-
tion refractory mutation detection system (Newton et al.,
1989) noreversion to wt DHBV3 was detected at a ratio of
1:1000 (data not shown).
Discussion
With mammalian hepadnaviruses, functional X protein
plays an important though as yet undefined role in the full
process of in vivo infection. DHBV strains contain an X
ORF without an AUG start codon, but an X-like protein has
recently been identified in DHBV-infected liver, and DHBx
is expressed in vitro by wt but not DHBV3-X-K.O. Using in
vitro assays, transactivation and apoptosis were shown to be
markedly reduced when expression of DHBx was prevented
by introducing a stop codon into the X-like ORF (Chang et
al., 2001; Schuster et al., 2002).
In this study we have used the same DHBV DNA con-
structs as in the above work and a number of sensitive
measures of in vivo fitness to examine whether a functional
DHBx protein contributes to the in vivo infection process.
The ultimate aim was to clarify the mechanism of any
observed effect. We used the criteria of (i) quantitation of
serum DHBV DNA, proteins, and infectivity in infected
ducks with stable viraemia; (ii) the comparison of rate of
spread of infection in liver and extrahepatic sites after low-
dose inoculation; and (iii) the comparison of ability to
produce transient or persistent infection under balanced
age/dose conditions designed to detect small differences
between the strains. No significant difference was seen
between wt and DHBV3-X-K.O. strains by any of these
measures. Furthermore, unlike the situation described with
WHV (Zhang et al., 2001), the DHBV3-X-K.O. strain did
not revert to wt as examined by direct sequencing of am-
plified viral DNA in any of the ducks tested, again providing
Table 2
The determination of viraemia in ducks from the age/dose experiment
Dose DHBV3 wt DHBV3-X-K.O.
104 ID50 2/8a 3/8
106 ID50 4/8 1/8
108 ID50 8/8 8/8
Total 14/24 12/24
a Number of persistently infected ducks/total number of ducks inocu-
lated.
Fig. 3. DHBsAg and DNA in serum during spread of virus in the liver. (A)
DHBsAg was detected and quantitated by ELISA. Each symbol represents
the DHBsAg serum content of one duck determined by end-point titration
as described under Materials and methods. DHBsAg was first detected at
day 6 p.i. Serum DHBsAg levels in all ducks peaked at around day 9 p.i.
and then declined by 0.5–1 log. (B) Total DNA was extracted from serum
samples and DHBV DNA was quantitated using LightCycler FastStart
DNA Master SYBR Green I. Each symbol represents the DHBV DNA
content of one duck. DHBV DNA was first detected at day 3 p.i., peaked
at day 9 p.i., and then declined by 0.5–1 log. The detection limit was
equivalent to 1.1  104 DNA copies/ml.
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no evidence for enhanced capacity of the wt virus to main-
tain infection in vivo.
Neither our current nor previous studies exclude expres-
sion of very low amounts of DHBx-like proteins from the
DHBV3-X-K.O. genome that might be produced by trans-
lational read-through of the introduced stop codon or by
translational initiation downstream of the stop codon at a
nonconventional start codon. In addition, reversion of a
minor fraction of DHBV3-X-K.O. to wt cannot be excluded
by direct sequencing of amplified DNA or other methods.
Both possibilities may provide sufficient DHBx for its in
vitro and in vivo function. Furthermore, the possibility re-
mains that X protein may play other role(s) in vivo that
might not have been revealed in the above experiments, for
example, during infection of adult ducks, in survival under
natural conditions of transmission in ovo, or in host range
specificity. The conservation of the X-like ORF across all
the avihepadnaviruses suggests that some selection pressure
may be operating in favor of X retention. On the other hand,
the loss of the AUG in the X ORF of DHBV may indicate
that, specifically with DHBV, this process may not be crit-
ical for virus survival.
Interestingly, recent in vitro experiments with HBV
showed similar results to ours using HBV constructs in
which HBx was knocked out (HBx-K.O.) and/or in which
the phosphorylation sites in the PreS2 part of the large
surface protein (LHBs) were mutated (LHBs-def.). These
experiments showed that in the supernatant of HepG2 cells
transfected with HBx-K.O. or LHBs-def. constructs, no
significant differences in levels of viral DNA, HBsAg, or
HBeAg were observed compared to wt transfected cells
(Stockl et al., 2003). However, using a double-mutant HBx-
K.O. combined with LHBs-def., a complete loss of HBsAg
and HBeAg secretion was observed as well as dramatically
diminished levels of viral DNA. HBV expression could be
rescued by adding a fusion protein composed of a cell-
permeable translocation motif (TLM) fused to either HBx or
LHBs (Hafner et al., 2003). These results show that either
HBx or functionally active LHBs are essential and sufficient
for HBV gene expression. It would be interesting to deter-
mine if DHBV strains with mutations in both DHBx and
DHBV PreS/S show a similar phenotype.
Materials and methods
Animals
One- to 2-day-old DHBV-negative Pekin–Aylesbury
ducks (Anas domesticus platyrhyncos) were obtained from
commercial duck hatcheries and held in the animal house
facilities of the Institute of Medical and Veterinary Science
(IMVS), Adelaide. All animal handling procedures were
approved by both the IMVS and the University of Adelaide
Animal Ethics Committees and followed the guidelines of
the NHMRC.
Plasmids
The plasmid DNA used contained head-to-tail dimers of
the genomes of DHBV3 (pDHBV3) or DHBV3-X-knock
out (pDHBV3-X-K.O.) (Chang et al., 2001). The pDHBV3-
X-K.O. carried a G-to-A change at nucleotide position 2371
of the DHBV3 strain, converting the codon for tryptophan
(TGG) at amino acid position 28 in the X-like ORF into a
stop codon (TAG). This change did not affect the overlap-
ping ORF of the polymerase gene. Plasmid stocks were
generated using commercial kits and the mutation in
pDHBV3-X-K.O. was verified by direct sequencing of plas-
mid DNA.
DNA inoculation and DHBV infection
For the generation of viral stocks eight 1- to 2-day-old
DHBV-negative ducks were inoculated ih (1305, 1308), iv
(1304, 1307), or using combined routes ih and iv (1306,
1309, 1310, 1311) with 100 g of pDHBV3 (1304, 1305,
1309, 1310, 1311) or pDHBV3-X-K.O. (1306, 1307, 1308)
diluted in saline. The DHBV DNA and DHBsAg content of
subsequent serum samples was determined by quantitative
PCR and quantitative DHBsAg ELISA. For the determina-
tion of the ID50 of viral stocks, six groups of three 1- to
2-day-old DHBV-negative ducklings were inoculated iv
with serial dilutions of the stocks of DHBV3 or DHBV3-
X-K.O. analyzed above, using normal duck serum (NDS) as
the diluent and containing the equivalent of 10,000, 1000,
100, 10, 1, and 0.1 viral genomes per inoculum dose. To
analyze the spread of infection in the liver, two groups of 24
1- to 2-day-old DHBV-negative ducks were inoculated iv
with 1500 ID50 of either DHBV3 or DHBV3-X-K.O., and
each day from days 3 to 14 p.i., two ducks from each group
were sacrificed and blood and tissue from liver, spleen,
pancreas, and kidney were collected. Histological analysis
and detection of DHBsAg were performed as described
below. For the age/dose-related outcome, a total of six
groups of eight 14-day-old DHBV-negative ducks were
inoculated iv with 104, 106, or 108 ID50 of either DHBV3 or
DHBV3-X-K.O., and the outcome of infection was moni-
tored by detection of DHBsAg and DHBV DNA in serum.
Serological assays
To detect DHBsAg, ELISA plates (Costar 3590) were
coated with a 1:100 dilution of test serum and blocked with
5% skim milk in PBS/0.05% Tween (Jilbert et al., 1996).
DHBsAg was detected using 1H.1 monoclonal anti-DHBV
preS antibodies (Pugh et al., 1995) at a dilution of 1:5000
followed by HRP-conjugated sheep anti-mouse IgG F(ab)2
(Amersham, 1:4000) with the peroxidase substrate o-phe-
nylene diamine (OPD; Sigma) and plates were read at 490
nm. The DHBsAg content of each sample was determined
by end-point titration of serum samples using a pool of
serum from congenitally DHBV-infected ducks (containing
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50 g/ml DHBsAg) (Jilbert et al., 1996) as a standard. NDS
was added to the standard at the same dilution as the
samples being tested, i.e., for samples diluted 1:1000, stan-
dards were diluted twofold from 1:500 to 1:256,000 and
NDS diluted 1:1000 was added to each of the standards. For
the analysis of liver enzymes in serum, samples were tested
for levels of AST, ALT, and GGT using an automatic
analyzer in the Diagnostic Services Laboratories of the
IMVS. The normal range for the level of each enzyme in
NDS was determined to be 15.9 5.9 U/L for AST, 26.6
7.7 U/L for ALT, and 2.3  1.2 U/L for GGT (Foster et al.,
2003).
Detection and quantification of serum DHBV DNA by
PCR and sequencing of PCR-amplified fragments
DHBV DNA was isolated from serum samples using
High Pure Viral Nucleic Acid Kit (Roche) that included
proteinase K treatment in the first step. The DHBV DNA
content was determined by quantitative PCR (Roche Light-
Cycler) using LightCycler FastStart DNA Master SYBR
Green I (Roche). A plasmid containing a head-to-tail dimer
of AusDHBV DNA was used as a standard (Triyatni et al.,
2001). Samples consisted of 1 l of duck serum extract
diluted 1:100 (equivalent to 0.04 l of duck serum), 2 l of
FastStart DNA Master SYBR Green I, 2.4 l MgCl2 (final
concentration 4 mM), 0.5 l of 10 M primers (final con-
centration for each primer 0.25 M) in a total of 20 l.
Primers used for quantitative PCR were located in con-
served regions of the surface (S) ORF of AusDHBV: P3 (5
AGCTGGCCTAATCGGATTAC3) was located at nt
1316–1335 and P4 (5TGTCCGTCAGATACAGCAAG3)
was located at nt 1565–1584. For sequencing, serum DHBV
DNA was precipitated by polyethylene glycol, and the X
ORF region was amplified using primers P1 (5CAACA-
CATGGCGCAATATCC3), located at nt 2175–2194, and
P2 (5TGTGTAGTCTGCCAGAAGTC3) located at nt
2821–2840. For the sequencing reaction, the BigDye Ter-
minator v3.0 cycle sequencing kit (Applied Biosystems)
was used according to the manufacturer’s protocol with
primer P1 as the sequencing primer. Analysis was per-
formed on an ABI Prism 3700.
Tissue analysis
For Western blot analysis, duck liver was homogenized
in PBS containing 0.5% NP-40 to give a 10% homogenate.
The total protein content of the homogenates was deter-
mined using a commercial protein determination assay
(Bio-Rad). Samples containing 100 g of total protein were
mixed with sodium dodecyl sulphate (SDS) loading buffer
containing -mercaptoethanol, boiled, and separated by
SDS–polyacrylamide gel electrophoresis. Proteins were
blotted onto Hybond ECL nitrocellulose membranes (Am-
ersham) that were blocked overnight with 5% skim milk.
DHBsAg was detected using 1H.1 (1:5000) and HRP-con-
jugated sheep anti-mouse Ig F(ab)2 (1:4000). DHBcAg was
detected using rabbit anti-recombinant DHBcAg antibodies
(1:1000) (Jilbert et al., 1992), followed by a goat anti-rabbit
serum containing HRP (1:4000; KPL, Gaithersburg, MD,
USA) and ECLplus (Amersham) and membranes were
exposed on Kodak X-OMAT AR. For Southern blot hybri-
disation, total DNA was isolated from 25 mg liver tissue
samples using a DNeasy tissue kit (Qiagen) that included
proteinase K treatment in the first step. Seven-microgram
samples of total DNA were loaded into each lane of a 1.2%
agarose gel, and blotting and detection using a 32P-labeled
probe was performed as described previously (Jilbert et al.,
1992). Immunohistological analysis was performed as fol-
lows: DHBsAg was detected in sections of ethanol:acetic
acid (EAA, 3:1) fixed, wax-embedded liver, spleen, pan-
creas, and kidney tissue, after blocking of endogenous per-
oxidase with H2O2, by standard immunoperoxidase staining
(Jilbert et al., 1996) using 1H.1 monoclonal antibodies fol-
lowed by HRP-conjugated sheep anti-mouse Ig F(ab)2
(Amersham) and diaminobenzidine (DAB; Sigma). Sec-
tions were counterstained with hematoxylin, dehydrated,
and mounted in Depex. Nuclei of hepatocytes staining pos-
itive for DHBsAg were counted with the aid of an eyepiece
graticule in 3–100 (most commonly 10) 250 250 m grid
fields and expressed as a percentage of the average total
hepatocyte nuclei counted in three representative grid fields
for each duck. Histological analysis was performed using
sections of formalin-fixed wax-embedded tissue stained by
haematoxylin and eosin (H&E).
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